Episode

Role of AKT and PI3K Inhibitors in Patients With HR-Positive Breast Cancers: Experts Share Their Thoughts on Current Practice and Future Opportunities

Podcast: Decera Clinical Education Oncology Podcast
Published: Apr 15, 2026
Duration seconds: 1882
Processing state: not_requested
Canonical source: https://oncologypodcast.simplecast.com/episodes/akt-and-pi3k-inhibitors-breast-cancer-SqsGu6ru
Audio: https://afp-928689-injected.calisto.simplecastaudio.com/1d8e143b-904e-45be-b6c5-8fba793d9d74/episodes/6935e156-672e-4fea-a484-5947fe514151/audio/128/default.mp3?aid=rss_feed&awCollectionId=1d8e143b-904e-45be-b6c5-8fba793d9d74&awEpisodeId=6935e156-672e-4fea-a484-5947fe514151&feed=GlfUTtJq
JSON: /v1/public/podcasts/decera-clinical-education-oncology-podcast-1302999/episodes/role-of-akt-and-pi3k-inhibitors-in-patients-with-hr-positive-breast-cancers-experts-share-their-thoughts-on-current-practice-and-future-opportunities
Markdown: /podcast/decera-clinical-education-oncology-podcast-1302999/role-of-akt-and-pi3k-inhibitors-in-patients-with-hr-positive-breast-cancers-experts-share-their-thoughts-on-current-practice-and-future-opportunities.md

Actions

POST https://stenobird.com/v1/public/podcasts/decera-clinical-education-oncology-podcast-1302999/episodes/role-of-akt-and-pi3k-inhibitors-in-patients-with-hr-positive-breast-cancers-experts-share-their-thoughts-on-current-practice-and-future-opportunities/transcription-requests
Idempotently request low-priority transcript generation for this episode.
GET https://stenobird.com/podcast/decera-clinical-education-oncology-podcast-1302999/role-of-akt-and-pi3k-inhibitors-in-patients-with-hr-positive-breast-cancers-experts-share-their-thoughts-on-current-practice-and-future-opportunities.md
Read the agent-friendly Markdown representation of this episode resource.

Summary

Listen to this podcast with Nadia Harbeck, MD, and Francois-Clement Bidard, MD, PhD, sharing their thoughts on the role of AKT and PI3K inhibitors in patients with primary or secondary endocrine-resistant breast cancers.